Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials

Journal of Market Access and Health Policy

Volumn 4, Issue 1, 2016, Pages

  Hanna, Eve ^a   Rémuzat, Cecile ^b   Auquier, Pascal ^a   Toumi, Mondher ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CREATIV CEUTICAL   (France)

Author keywords

advanced therapy medicinal products; ATMP; clinical trials; RCT; risk of discontinuation

Indexed keywords

EID: 85033601135     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v4.32232     Document Type: Article

References (20)

1. Directive 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_fr.pdf [cited 5 May 2016].
2. Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf [cited 5 May 2016].
3. Hanna E, Remuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: Current and future perspectives. J Mark Access Health Policy. 2016; 4: 31036, doi: http://dx.doi.org/10.3402/jmahp.v4.31036.
4. Meldrum ML. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematol Oncol Clin North Am. 2000; 14(4):745–60. [PubMed Abstract] vii.
5. Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important?. BMJ. 1998; 316: 201.
6. Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014; 5(1):e45. doi: http://dx.doi.org/10.1038/ctg.2013.13.
7. World Health Organization (WHO). Health promotion evaluation: Recommendations to policymakers. Report of the WHO European working group on health promotion evaluation. 1998; Copenhagen, Denmark: WHO.
8. Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, etal. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001; 322(7286):603–6.
9. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A, etal. Discontinuation and non-publication of surgical randomised controlled trials. Observational study BMJ. 2014; 349: 6870.
10. Lopienski K. Retention in clinical trials–Keeping patients on protocol, June 2015. Available from: http://forteresearch.com/news/infographic-retention-in-clinical-trials-keeping-patients-on-protocols/ [cited 5 May 2016].
11. Svennebring AM, Wikberg JE. Net present value approaches for drug discovery. Springer Plus. 2013; 2 140. doi: http://dx.doi.org/10.1186/2193-1801-2-140.
12. Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, etal. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014; 311(10):1045–51.
13. Kaitin K, DiMasi J. Pharmaceutical innovation in the 21st Century: New drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther. 2011; 89: 183–8. doi: http://dx.doi.org/10.1038/clpt.2010.286 [PubMed Abstract].
14. Mullard A. New drugs cost US$2.6 billion to develop. Nat Rev Drug Discov. 2014; 13 877. doi: http://dx.doi.org/10.1038/nrd4507.
15. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and opportunities: Workshop summary. 2010; Washington (DC): National Academies Press (US).3, Challenges in clinical research. Available from: http://www.ncbi.nlm.nih.gov/books/NBK50888/ [cited 5 May 2016].
16. Stensland KD, Latif A, Hendricks R, Roper N, McBride R, Hall SJ, etal.Prevalence and characteristics of prematurely terminated cancer clinical trials, 2013 ASCO Annual Meeting, 31 May 2013. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6613 [cited 5 May 2016].
17. Bernardez-Pereira S, Lopes RD, Carrion MJ, Santucci EV, Soares RM, de Oliveira AM, etal. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. Am Heart J. 2014; 168(2):213–9.
18. La Croix: Les médicaments du cancer atteignent un niveau de prix immoral.Entretien avec Jean-Paul Vernant. Available from: http://www.la-croix.com/Actualite/France/Les-medicaments-du-cancer-atteignent-un-niveau-de-prix-immoral-2013-11-06-1056577 (2013) [cited 1 April 2016].
19. Kantarjian H, Steensma D, Rius SJ, Elshaug A, Light D. High cancer drug prices in the United States: Reasons and proposed solutions. J Oncol Pract. 2014; 10: e208–11.
20. Pfister DG. The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution. J Clin Oncol. 2013; 31: 3487–9.